Equities

Skye Bioscience Inc

SKYE:NMQ

Skye Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.17
  • Today's Change-0.11 / -2.57%
  • Shares traded100.88k
  • 1 Year change+159.01%
  • Beta1.7400
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1.431.248.98
Total Receivables, Net0.03----
Total Inventory------
Prepaid expenses0.430.850.57
Other current assets, total9.766.850.06
Total current assets128.949.61
Property, plant & equipment, net0.280.160.23
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.010.010.01
Total assets129.119.86
LIABILITIES
Accounts payable1.161.790.90
Accrued expenses2.072.120.98
Notes payable/short-term debt4.370.060
Current portion long-term debt/capital leases01.851.97
Other current liabilities, total6.306.300.06
Total current liabilities14123.91
Total long term debt000
Total debt4.371.901.97
Deferred income tax------
Minority interest------
Other liabilities, total0.1700.08
Total liabilities14123.99
SHAREHOLDERS EQUITY
Common stock0.010.910.48
Additional paid-in capital1026353
Retained earnings (accumulated deficit)(104)(67)(47)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(2.13)(3.01)5.86
Total liabilities & shareholders' equity129.119.86
Total common shares outstanding123.651.90
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.